|
 4th Lyophilisation Conference7th - 9th September 2010, The Window, 13 Windsor Street, Islington, London, UK With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today. Mirroring this trend, the market for lyophilising these compounds, currently approaching 200 million units, is set to continue its year-on-year double digit growth. ...more details |
 Glaucoma & Retinopathies 201021st - 22nd June 2010, BSG House, London, UK The global market for ophthalmic pharmaceuticals is a profitable and prestigious segment, with total sales of $32.4bn forecast by 2025. With an increasingly ageing population and rates of diabetes soaring worldwide, glaucoma and retinal diseases will rise significantly over the next 10 years. All three remain significant unmet needs and constitute the largest and fastest-growing categories for pharmacotherapy. ...more details |
 6th Annual Monoclonal Antibodies24th - 26th May 2010, BSG Conference Centre, London, UK With more than 25 products in clinical use worldwide, including eight blockbusters, monoclonal antibodies have arrived as therapeutics. The global monoclonal antibodies market, worth $41bn in 2010, remains one of the most exciting and promising areas within the world pharmaceutical market today. ...more details |
 eCTD London Summit20th - 21st May 2010, BSG Conference Centre, London, UK eCTD is an interface for the pharmaceutical industry to agency transfer of regulatory information. In July 2009, the EMEA have made it clear that paper and other electronic formats will be an exception to the general e-CTD format recommended for any application. As it is not limited to the transfer of information it also applies to the creation, review, life cycle management and archival of electronic submission. Hence, drug manufacturers must consider new methodologies and adapt their organisation to change. ...more details |
 2nd Annual Vaccine Manufacturing Conference11th - 12th May 2010, BSG Conference Centre, London, UK During the period 2008-2013, the most important development in influenza vaccines, will be the diversification of influenza manufacturing. New cell-based technologies will be used, and eventually replace, existing egg-based manufacturing methods. Many cell-culture vaccines are being developed under grants from the US government. ...more details |
 Pricing & Reimbursement for Medical Devices15th - 16th April 2010, BSG Conference Centre, London, UK Medical devices manufacturers require a more rigorous and strategic approach to safeguard product prices and prevent competition. Innovative manufacturers that have integrated their pricing and product strategies will achieve exceptional growth and profitability in this changing environment. ...more details |
 Pre-filled Syringes Americas12th - 14th April 2010, The Colonnade Hotel, 120 Huntington Avenue, Boston, USA Pre-filled syringes and injection devices are now regarded as the delivery method of choice for a wide range of parental products. According to industry research, the current market for pre-filled syringes is expected to reach 2.5 billion units by 2010. The growth rate is to be expected to remain at a high level of more than 10% annually due to a number of factors such as greater medication safety and increased convenience from using a pre-fillable device. However, there are some challenges and potential threats to syringe and needle supply manufacturers. ...more details |
 3rd Annual Packaging and Labelling Congress13th - 14th April 2010, BSG House, London, UK Pharmaceutical packaging and labelling is considered an essential aspect of the product. The role of packaging and labelling has increased considerably and constantly advancing over the last few decades. This area has been experiencing emerging regulatory issues and stringent restraints. ...more details |
 Translational Regenerative Medicine 30th - 31st March 2010, BSG House, London, UK Regenerative medicine is set to revolutionise healthcare as stem cell, tissue engineering, gene therapy and materials science come together to transform patient treatment. Bringing you the latest in translational applications from leading experts, don't miss this exceptional showcase of medical innovations in this fast-moving field. ...more details |
 3rd Annual Biomarkers Conference23rd - 24th March 2010, BSG Conference Centre, London, UK Pharmaceutical and biotech companies are looking for new ways to increase the efficiency of drug discovery process while minimising costs and time for approvals. Biomarkers are fast becoming an essential part of clinical development from discovery to approval. According to industry research, the global biomarker market is estimated to be $20.5 billion by 2014, growing at a CAGR of 19.7%. ...more details |
|